You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華海藥業(600521.SH):上半年淨利潤同比預減約40%到50%

格隆匯7月14日丨華海藥業(600521.SH)公佈2025年半年度業績預告,公司2025年半年度實現歸屬於上市公司股東的淨利潤預計在37,400萬元至44,900萬元之間,同比下降約40%到50%。公司2025年半年度歸屬於上市公司股東的扣除非經常性損益的淨利潤預計在34,400萬元至42,100萬元之間,同比下降約45%到55%。

報告期內,公司實現歸屬於上市公司股東的淨利潤及歸屬於上市公司股東的扣除非經常性損益的淨利潤較去年同期下降,主要系:1、隨着國內集採政策的深化、原料藥行業競爭的加劇及中美關稅影響,公司產品市場份額雖不斷提升,但價格的持續下跌影響公司本期銷售收入同比出現下降,影響利潤同比減少;2、報告期內,公司加快生物創新藥研發項目的推進進度,相應研發投入同比大幅增加;3、本期外幣匯率變動影響匯兌收益同比減少。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account